Two Sigma Investments LP Boosts Stake in Medifast, Inc. (NYSE:MED)

Two Sigma Investments LP increased its stake in shares of Medifast, Inc. (NYSE:MED - Free Report) by 11.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 232,069 shares of the specialty retailer's stock after purchasing an additional 23,822 shares during the quarter. Two Sigma Investments LP owned 2.12% of Medifast worth $4,089,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Federated Hermes Inc. grew its stake in Medifast by 28.8% during the 4th quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer's stock worth $4,924,000 after purchasing an additional 62,574 shares in the last quarter. Geode Capital Management LLC grew its stake in Medifast by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 245,929 shares of the specialty retailer's stock worth $4,335,000 after purchasing an additional 1,447 shares in the last quarter. American Century Companies Inc. grew its stake in Medifast by 3.4% during the 4th quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer's stock worth $4,303,000 after purchasing an additional 8,058 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Medifast by 103.9% during the 4th quarter. JPMorgan Chase & Co. now owns 117,157 shares of the specialty retailer's stock worth $2,064,000 after purchasing an additional 59,702 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new position in Medifast during the 4th quarter worth $1,938,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. DA Davidson lowered their target price on Medifast from $17.00 to $16.50 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Wall Street Zen raised Medifast from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st.

Medifast Stock Performance

NYSE MED traded down $0.77 during trading on Monday, reaching $13.30. 231,942 shares of the company's stock were exchanged, compared to its average volume of 287,157. The stock has a market cap of $146.18 million, a P/E ratio of 73.89 and a beta of 0.96. The company has a 50 day moving average price of $13.04 and a two-hundred day moving average price of $15.20. Medifast, Inc. has a 1 year low of $11.57 and a 1 year high of $26.07.

Medifast (NYSE:MED - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.04). The business had revenue of $115.73 million for the quarter, compared to analysts' expectations of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%. Research analysts forecast that Medifast, Inc. will post 0.51 EPS for the current fiscal year.

Medifast Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.